Vyxeos
Author: Rachael Lloyd
Publisher: Datamonitor Healthcare
- Description
- Contents
- Enquire
Drug Overview
Vyxeos (cytarabine/daunorubicin; Jazz Pharmaceuticals) is a liposomal formulation of a 5:1 molar ratio of cytarabine and daunorubicin – chemotherapy drugs which are currently administered as two separate intravenous injections as part of the 7+3 regimen for the treatment of acute myeloid leukemia. The delivery of cytarabine/daunorubicin combination therapy to cancer cells at this fixed ratio is thought to optimize anti-cancer activity, and encapsulation of the drugs in the liposome increases the time that the patient is exposed to the drug post-administration.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 Vyxeos : Acute myeloid leukemia (AML)
LIST OF FIGURES
9 Figure 1: Vyxeos for acute myeloid leukemia – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of Vyxeos for acute myeloid leukemia
11 Figure 3: Datamonitor Healthcare’s drug assessment summary of Vyxeos for acute myeloid leukemia
LIST OF TABLES
5 Table 1: Vyxeos drug profile
7 Table 2: Vyxeos late-phase data in acute myeloid leukemia
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Oral Vidaza 
Sign up to the